Inversago Pharma

OverviewSuggest Edit

Inversago Pharma is a specialized, preclinical-stage biotech company. The Company develops cannabinoid-1 receptor blockers and antagonists for the treatment of prader-willi syndrome, diabetes, obesity, and other metabolic disorders.
TypePrivate
Founded2015
HQMontreal, CA
Websiteinversago.com

Latest Updates

Employees (est.) (Jun 2019)5
Cybersecurity ratingAMore

Inversago Pharma Office Locations

Inversago Pharma has an office in Montreal
Montreal, CA (HQ)
1 Place Ville Marie #1670
Show all (1)

Inversago Pharma Financials and Metrics

Summary Metrics

Founding Date

2015

Inversago Pharma total Funding

$42 m

Inversago Pharma latest funding size

$35 m

Time since last funding

3 months ago

Inversago Pharma investors

Inversago Pharma's latest funding round in September 2020 was reported to be $35 m. In total, Inversago Pharma has raised $42 m
Show all financial metrics

Inversago Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Inversago Pharma Online and Social Media Presence

Embed Graph

Inversago Pharma Blogs

Inversago Pharma continues to rapidly expand its leadership team and appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer

MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’…

Inversago Pharma Appoints Michael D. Harvey, PhD as Senior Vice President, Drug Development

MONTREAL (CANADA) – October 13, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing…

Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker

MONTREAL (CANADA) – September 29, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prade…

Media talk about Inversago Pharma

MONTREAL (CANADA) – September 28, 2020 – The Globe & Mail, BioteCanada’s Insights magazine and Endpoints News recently published articles about Inversago Pharma. The Globe & Mail – Investors bet $35-million on Montreal startup’s effort to revive failed class of weight-loss drugs by Sean Silc…

Inversago Pharma Frequently Asked Questions

  • When was Inversago Pharma founded?

    Inversago Pharma was founded in 2015.

  • How many employees does Inversago Pharma have?

    Inversago Pharma has 5 employees.

  • Who are Inversago Pharma competitors?

    Competitors of Inversago Pharma include GB Sciences, Greenwich Biosciences and Tilray.

  • Where is Inversago Pharma headquarters?

    Inversago Pharma headquarters is located at 1 Place Ville Marie #1670, Montreal.

  • Where are Inversago Pharma offices?

    Inversago Pharma has an office in Montreal.

  • How many offices does Inversago Pharma have?

    Inversago Pharma has 1 office.